Aceto has acquired A&C, a global manufacturer of specialty excipients, buffers, and process solutions. The acquisition is aimed to help drive Aceto’s growth strategy, increasing the company’s GMP manufacturing, packaging, and ingredients offerings for the cell culture, vaccine, and biopharmaceutical industries. It will also expand the company’s North American footprint.
With A&C, Aceto hopes to provide customers greater access to critical raw materials and excipients used in synthesising biologics, as well as support throughout the drug development process.
“With the acquisition of A&C, Aceto has materially expanded its self-manufactured and custom product offerings in the vaccine and biopharmaceutical space,” said Gilles Cottier, CEO of Aceto. “Across all of our recent acquisitions, including Syntor and IsleChem, Aceto can now offer customers an extensive selection of highest quality and competitively priced products and services to help customers secure and optimize critical supply as well as bring new products to market globally.”
“A&C is a service-driven organization with a mission of finding unique solutions to customers’ GMP challenges and supporting them through all stages of the development cycle,” said Ken McCracken, President & CEO of A&C. “This fundamental approach to our business perfectly aligns with Aceto’s value proposition and customer-centric service philosophy. We are excited to provide customers a differentiated, integrated suite of product offerings.”
Aceto says it will continue to support A&C’s manufacturing facilities and offices in the US, Canada, and Ireland.